1350352-70-3 Usage
Description
Febuxostat Impurity 7, also known as 3-Descyano-3-((hydroxyimino)methyl) Febuxostat, is an impurity found in Febuxostat (F229000), which is a xanthine oxidase/xanthine dehydrogenase inhibitor. This impurity is significant in the pharmaceutical industry due to its association with the active drug Febuxostat.
Uses
Used in Pharmaceutical Industry:
Febuxostat Impurity 7 is used as a reference material for the development and validation of analytical methods in the pharmaceutical industry. Its presence in the active drug Febuxostat necessitates the need for accurate quantification and quality control measures to ensure the safety and efficacy of the final drug product.
Febuxostat Impurity 7 is also used as a research compound for studying the effects of impurities on the pharmacokinetics, pharmacodynamics, and overall performance of Febuxostat in treating hyperuricemia and chronic gout. Understanding the role of this impurity can help in optimizing the drug formulation and minimizing potential side effects.
Additionally, Febuxostat Impurity 7 may be utilized in the development of new drugs or drug candidates with similar mechanisms of action, as understanding the structure-activity relationship of such impurities can provide valuable insights for drug design and development.
Check Digit Verification of cas no
The CAS Registry Mumber 1350352-70-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,0,3,5 and 2 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1350352-70:
(9*1)+(8*3)+(7*5)+(6*0)+(5*3)+(4*5)+(3*2)+(2*7)+(1*0)=123
123 % 10 = 3
So 1350352-70-3 is a valid CAS Registry Number.
1350352-70-3Relevant articles and documents
PROCESS FOR THE PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
-
, (2011/12/02)
The present invention relates to novel and improved processes for the preparation of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1 and its pharmaceutically acceptable salts thereof. the present invention also provides the novel process for the preparation of crystalline forms of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1 and its intermediates.
